Table 1 Univariable associations between Oclacitinib treated patients (cases) and patients treated with other therapies (controls)

Age

< 0.001

1 to 4 years

Reference

 > 4 to 8 years

0.88 (0.77–1)

0.053

 > 8 years

0.58 (0.49–0.68)

< 0.001

 Male

Reference

0.676

 Female

0.97 (0.85–1.10)

 Neutered

Reference

< 0.001

 Entire

0.68 (0.56–0.82)

Breeds

< 0.001

 Small

Reference

 Medium

0.54 (0.44–0.65)

< 0.001

 Large

0.5 (0.42–0.59)

< 0.001

 All antimicrobials

0.73 (0.63–0.85)

< 0.001

 All glucocorticoids

0.58 (0.48–0.72)

< 0.001

 Topical antimicrobials

0.65 (0.52–0.81)

< 0.001

 Systemic antimicrobials

0.69 (0.58–0.82)

< 0.001

 Topical glucocorticoids

0.67 (0.54–0.84)

< 0.001

 Systemic glucocorticoids

0.47 (0.37–0.6)

< 0.001

 Antihistamines

0.39 (0.26–0.57)

< 0.001

 Cephalexin

0.76 (0.64–0.91)

0.003

 Cefovecin

0.67 (0.43–1.04)

0.076

 Chlorhexidine (2–5%)

0.53 (0.39–0.72)

< 0.001

 Neomycin

0.38 (0.27–0.53)

< 0.001

 Polymixin B

0.77 (0.57–1.04)

0.091

 Amoxycillin plus clavulanic acid

0.47 (0.34–0.66)

< 0.001

 Allergy testing (yes/no)

3.62 (1.18–11.11)

0.025

 Hypoallergenic diet

1.25 (0.9–1.73)

0.175

 Medicated shampoo

0.51 (0.38–0.68)

< 0.001

 Flea treatments

0.81 (0.65–1.01)

0.067

 Non-infectious allergic dermatitis

Reference

< 0.001

 No evidence of concurrent skin infection

0.62 (0.43–0.89)

0.008

 Superficial pyoderma

1.41 (1.41–2.92)

< 0.001

 Deep pyoderma

Omitted

 No infectious agents present

Reference

0.1043

 Cocci present

0.97 (0.63–1.50)

0.907

 Rods present

0.40 (0.13–1.28)

0.124

 Malassezia present

1.23 (0.97–1.56)

0.079